ONGOING STUDIES

Study title: Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second line therapy in head and neck cancer.

Summery: Head and neck cancer is one of the commonest cancers seen in India. Unfortunately, 85% of patients are seen in the advanced stage. Hence most of the patients fail. Palliative chemotherapy (chemotherapy which is given for symptomatic relief to have good quality of life. This chemotherapy cannot cure the cancer) is one of the main treatment options in this situation. There is an urgent need for having effective medical treatment options for such patients. Immunotherapy is a new treatment option in multiple cancers. However, the cost of these immunotherapy medications makes this option unfeasible for majority of the patients.

Metronomic chemotherapy has been developed as a cost-effective palliative chemotherapy option in head and neck cancers. There are multiple options of treatment in advanced cancer. However metronomic chemotherapy is oral, cheap and requires minimum resources. Hence in this study we will be comparing the physician’s choice of standard therapy and triple metronomic therapy with each other.